
|Videos|May 8, 2013
The Presence of a BRCA Mutation in Patients with Breast Cancer
Author(s)Penny Daugherty, RN, MS, OCN
Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.
Advertisement
Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.
Clinical Pearls
While a BRCA mutation used to be considered a negative prognostic factor in patients with breast cancer, it can now be considered a good thing, Daugherty says. Patients with the BRCA mutation are more amenable to platinum therapy and are eligible for PARP trials. It remains important for nurses and doctors to inform patients about new knowledge concerning BRCA.
- While the presence of a BRCA mutation used to be considered negative, it can now be considered positive, Daugherty says
- Patients with BRCA mutations are more amenable to platinum therapy and are eligible for PARP trials
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
5






































